Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Neuro-OncologyOpen Access

DDDR-36. Tirabrutinib Therapy for Refractory or Relapsed Primary Central Nervous System Lymphoma: A Retrospective Analysis of 13 Cases

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNoritaka SanoKSKoji ShiomiEYEtsuko Yamamoto

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds 61.5% efficacy in 13 PCNSL patients receiving tirabrutinib, indicating favorable outcomes and manageable adverse events.

Key Points

  • This study aims to evaluate tirabrutinib's efficacy and safety in treating refractory or relapsed primary central nervous system lymphoma.
  • Retrospective analysis of 13 patients with PCNSL treated with tirabrutinib at Kyoto University Hospital.
  • Evaluated patient characteristics, prior treatments, radiological response, and Karnofsky Performance Status for ADL assessment.
  • Assessed progression-free survival (PFS), overall survival (OS), and treatment-related adverse events.
  • Overall response rate was 61.5%.
  • Median PFS was 10 months, mean PFS was 7.3 months.
  • Median OS was 18 months, with maintained or improved ADL in most cases.
  • Adverse events included mucocutaneous inflammation and cytopenia, with 15.4% needing dose modification.

Cite This Study

Sano et al. (2025) studied this question.

synapsesocial.com/papers/69254362c0ce034ddc358280https://doi.org/10.1093/neuonc/noaf201.0673
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P17.14.B A RETROSPECTIVE STUDY OF THE BTK-INHIBITOR TIRABRUTINIB FOR THE TREATMENT OF RECURRENT/REFRACTORY PRIMARY CNS LYMPHOMA2025
  2. 2Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of central nervous system.2024
  3. 3CTNI-16. PATIENT BACKGROUNDS ASSOCIATED WITH THE PROLONGED EFFECTIVENESS OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: RESULTS FROM THE ROSETTA STUDY2025
  4. 4Durable Complete Remission Achieved by Tirabrutinib Rechallenge in Relapsed Primary Central Nervous System Lymphoma: A Case Report2026
  5. 5Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma2025